Drug class
Recombinant human coagulation factor IX Fc-fusion protein (extended half-life)
Mechanism of action
Replaces deficient factor IX in haemophilia B. Activated factor IX forms a complex with activated factor VIII on phospholipid surfaces and activates factor X, supporting thrombin generation and haemostasis.
General use cases
- Treatment and prophylaxis of bleeding in congenital haemophilia B (factor IX deficiency), across age groups under the cited EMA product information
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
